If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
We are pleased to announce that a new article entitled ‘Cluster analyses from the real-world NOVELTY study: six clusters across the asthma-COPD spectrum’ has been published in the Journal of Allergy and Clinical Immunology: In Practice.
Asthma and COPD are heterogeneous, with many patients displaying features of both conditions; however, treatment recommendations markedly differ between these diagnoses. This article reports cluster analyses of clinical and physiological features and readily available biomarkers in patients with physician-assigned diagnoses of asthma and/or COPD in NOVELTY to investigate whether these clusters identify distinct patient groups that might indicate specific underlying pathways or suggest future treatment targets, irrespective of diagnosis.
Results from the analyses identified six overlapping clusters, reflecting the overlapping clinical and biological characteristics of patients included in these clusters, suggesting that they do not reflect discrete underlying mechanisms. All clusters included patients with asthma, asthma+COPD and COPD, and had several discriminatory features that differed from conventional diagnostic characteristics.
This work highlights the heterogeneity and overlap between features of asthma, asthma+COPD and COPD in patients in a real-world setting, contrasting with the siloed populations with asthma or COPD on which current management guidelines are based. Identification of molecular endotypes and potential treatment targets across the spectrum of obstructive lung disease is required to enable a precision medicine approach.
Read a summary of this article, and other NOVELTY publications and presentations here.